Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer.

Primary tabs

field_vote: 
Average: 2 (1 vote)
Other Key Words:: 
Publication type: 
Therapeutic Substance(s): 
References: 

Cancer Lett. 2009 Oct 8;283(2):119-24. Epub 2009 Feb 15.

Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer.

Xu FG, Ma QY, Wang Z.
Department of Surgery, First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an 710061, China.
Recent
studies have demonstrated that pancreatic adenocarcinoma cells require
hedgehog (HH) signaling for proliferation and survival. Mutations in
the smoothened (SMOH) gene and loss-of-function mutations in the
patched (PTCH) gene, which are involved in the HH signaling pathway,
may cause pancreatic tumors. Since HH signaling pathway may contribute
to the induction and maintenance of pancreatic tumors, the use of HH
pathway inhibitors for targeting the pancreatic cancer might represent
a novel therapeutic approach to advanced pancreatic carcinoma. Among
the HH inhibitors, cyclopamine inhibits HH signaling through direct
interaction with SMOH and retards the growth of cancer cells by
inhibiting stem cells. Novel therapies that target the HH signaling
pathway should become one of the more effective treatments for
pancreatic cancer, which cannot be cured with current therapies.